Thoracic surgeon Daniela Molena leads clinical trials to improve outcomes for people with esophageal cancers.
At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
Researchers want to find the best dose of abemaciclib to combine with radiation therapy to treat advanced breast cancer. The people in this study have metastatic breast cancer that is fueled by estrogen or progesterone (hormone receptor-positive cancer). In addition, their breast cancer does not make a protein called HER2.
The combination of radiation therapy and chemotherapy (chemoradiation) is a standard treatment for people with HPV-positive throat cancer. HPV is human papillomavirus and can cause throat cancer. Standard chemoradiation may cause severe side effects such as mouth and gut sores, sore throat, and changes in taste.
In this study, researchers are comparing a combination of two new drugs with standard treatment for ovarian cancer. The two drugs are avutometinib and defactinib. The people in this study have low-grade serous ovarian cancer that came back after treatment.
Researchers want to find the best dose of ADCLEC.syn1 that can be used in people with leukemia. The people in this study have acute myeloid leukemia (AML) that keeps growing even after treatment. There are currently no FDA-approved CAR T cell therapies for AML.
Researchers want to find the best dose of EVM14 when used alone or with pembrolizumab in people with solid tumors. The people in this study have a solid tumor that keeps growing after treatment and has spread. This study includes people with:
Researchers are finding the best dose of MB-CART19.1 immunotherapy in people with lymphoma. The people in this study have central nervous system lymphoma (CNSL) that came back or keeps growing after treatment.
This study is assessing the safety and effectiveness of ASTX727 in people who have malignant peripheral nerve sheath tumors (MPNST) with a mutation in a gene complex called PRC2 (EED or SUZ12). ASTX727 is a combination of two drugs (cedazuridine and decitabine) that have been designed to target cancer cells with a PRC2 complex genetic mutation and disrupt the cells' ability to survive and grow.
Rilvegostomig may help your immune system fight your cancer. It sticks to and blocks signaling from two molecules called PD-1 and TIGIT on immune cells. Cancer cells use PD-1 and TIGIT to avoid being attacked by the immune system so they can grow and survive. By stopping cancer cells from using these molecules, rilvegostomig may help your immune system find and attack cancer cells.
Prostate cancers initially need the male hormone testosterone for growth. Hormone therapies that lower the level of testosterone are among the best treatments for prostate cancers that have metastasized (spread). The benefits of hormone treatments often do not last, however. Over time, many prostate cancers keep growing even with hormonal therapies. These are called castration-resistant prostate cancers (CRPC).
Cancer and its treatment can cause problems with attention, memory, and learning. These cognitive difficulties may affect your daily activities and worsen your quality of life.
